BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
See today's BioWorld
Home
» Threshold Pharma halts tarloxotinib development; sees revival in evo, preclinical TH-3424
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Threshold Pharma halts tarloxotinib development; sees revival in evo, preclinical TH-3424
Oct. 3, 2016
By
Michael Fitzhugh
No Comments
Threshold Pharmaceuticals Inc. said it would discontinue development of EGFR-targeted tarloxotinib after the oncology candidate fell short of its expectations in dual phase II proof-of-concept trials.
BioWorld